WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Slides:

Advertisements

Similar presentations

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Advertisements

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Diabetes and Dyslipidemia

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Cholesteryl Ester Transfer Protein Inhibitors

PAD Patients vs Post-ACS Patients:

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Select Topics in Cardiovascular Medicine

Advances in Dyslipidemia: What Have We Learned From ACC 2017

What Do We Know About LDL-C?

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

TNT Study: Baseline Characteristics of the Patients

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

CV Risk Doesn't End in the Cath Lab

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Statins and HIV:.

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

CV Risk Doesn't End in the Cath Lab

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Monoclonal Antibodies in CVD: What Does the Future Hold?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Achieving Lipid Targets With PCSK9 Inhibition

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Late-Breaking Data on LDL-C Reduction

Translating Data From Trial to Practice

Presentation transcript:

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Risk of MI Associated With ApoB/ApoA1 Ratio

Statins Approximate LDL-C-Lowering Efficacy

Effect of Statins vs Placebo on CV Events

Lipid Goal Attainment in Asian Patients With ACS

PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy

PCSK9 CV Outcomes Trials

FOURIER Trial Design

FOURIER Endpoints

FOURIER Follow-Up

FOURIER: Baseline Characteristics

FOURIER: Lipid-Lowering Therapy and Lipid Levels at Baseline

FOURIER: Effect on LDL-C

FOURIER: Main CV Outcomes

FOURIER: Main CV Outcomes (cont)

FOURIER: Lower LDL-C Is Better

FOURIER: Safety

Summary of FOURIER

EBINGHAUS: Trial Design

Cognition and PCSK9 Inhibitors

EBINGHAUS Primary Endpoint: Spatial Working Memory Strategy Index

EBINGHAUS: Cognitive Assessments by Nadir Achieved LDL-C and Treatment

The SPIRE-1 and SPIRE-2 CV Outcome Trials

SPIRE-1 and SPIRE-2: Baseline Clinical Characteristics

SPIRE-1 and SPIRE-2: Confirmation of Attenuation in LDL-C Reduction Over Time

SPIRE-1 and SPIRE-2 Primary Prespecified Endpoint

SPIRE-1 and SPIRE-2: Incidence Rates of AEs per 100 P-Y of Exposure

ODYSSEY Outcomes Phase 3 Post-ACS With Alirocumab

PCSK9 CV Outcomes Trials

Abbreviations

Abbreviations (cont)

Abbreviations (cont)